


JAN. 28. 2003 2:05PM

AVENTIS US PAT DEPT

NO. 5261 P. 7

Applicants respectfully submit that this application, as amended above, is in condition for allowance. A Notice of Allowance is earnestly solicited.

Respectfully submitted,

  
F. Aaron Dubberley, Reg. No. 48,001  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone: 908-231-3737  
Telefax: 908-231-2626

Docket No. HMR2050

**Version With Markings to Show Amendments Made**

What is underlined has been added, and what is bracketed has been removed.

**IN THE SPECIFICATION:**

The 5<sup>th</sup> full paragraph on page 6:

Figure 7. BACTAPUC1 (pBTPH1) – Diagram of modified pBeloBAC11. The original vector was altered by including a modified polylinker region (SEQ ID NOs. 7 and 8) into which a high-copy PUC vector was inserted. In addition, by using a unique oligonucleotide adaptor, we have introduced the ability to utilize cloning based on single base extensions. See the AhdI sites provided by SEQ ID NOs. 3 – 6.

The 6<sup>th</sup> full paragraph on page 6:

Figure 8. pBTP2 – A further iteration of this vector removes an EcoRI site outside the polylinker and adds EcoRI to the polylinker. See SEQ ID NO. 9, before, and SEQ ID NO. 10, after.

The paragraph bridging pages 6 and 7:

Figure 9. pBTP3- Illustration of an adaptor system system which will allow for more efficient ligation. A BstXI restriction site is engineered into the vector such that only the appropriate modified insert (ligated with complementary adaptors, such as those shown by SEQ ID NOs. 11-14) will ligate.

**IN THE CLAIMS:**

13. (Amended) The vector [of claim 12, which is] pTRANS-SacB.
15. (Amended) The vector [of claim 14, which is] pTRANS.
18. (Amended) The vector [of claim 17, which is] pBacTA.PUC2.